Oosten Liesbeth E M, Koppers-Lalic Danijela, Blokland Els, Mulder Arend, Ressing Maaike E, Mutis Tuna, van Halteren Astrid G S, Wiertz Emmanuel J H J, Goulmy Els
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2300RC, Leiden, The Netherlands.
Int Immunol. 2007 Sep;19(9):1115-22. doi: 10.1093/intimm/dxm082.
CTLs specific for hematopoietic system-restricted minor histocompatibility antigens (mHags) can serve as reagents for cellular adoptive immunotherapy after allogeneic stem cell transplantation (SCT). In the HLA-mismatched setting, CTLs specific for hematopoietic system-restricted mHags expressed solely by the non-self 'allo' HLA molecules could be used to treat relapse after HLA-mismatched SCT. The generation of mHag-specific allo-HLA-restricted CTLs requires antigen-presenting cells (APCs) expressing low numbers of endogenous peptides to avoid co-induction of undesired allo-HLA reactivities. In this study, we exploited viral evasion strategies to generate APCs expressing a controlled set of endogenous peptides. Herpesviruses persist lifelong following primary infection due to expression of viral gene products that hamper T-cell recognition of infected cells. The herpesvirus-derived proteins US6, ICP47 and UL49.5 down-regulate endogenous antigen presentation in human APCs via inhibition of the transporter associated with antigen processing. EBV-transformed B cell lines transduced with retroviral vectors encoding US6, ICP47 or UL49.5 exhibited a stable decrease in cell-surface HLA class I expression and were protected from lysis by mHag-specific CTLs. Exogenous addition of mHag peptide fully restored target cell recognition. UL49.5 showed the most pronounced inhibitory effect, reducing HLA class I expression and mHag-specific lysis up to 99%. UL49.5 also significantly diminished allo-HLA reactivities mediated by allo-HLA-specific CTLs. In conclusion, UL49.5 could be a powerful new tool to study and modulate endogenous antigen presentation.
针对造血系统限制性次要组织相容性抗原(mHags)的细胞毒性T淋巴细胞(CTLs)可作为异基因干细胞移植(SCT)后细胞过继性免疫治疗的试剂。在HLA不匹配的情况下,仅由非自身“同种异体”HLA分子表达的造血系统限制性mHags特异性CTLs可用于治疗HLA不匹配SCT后的复发。产生mHag特异性同种异体HLA限制性CTLs需要表达少量内源性肽的抗原呈递细胞(APC),以避免意外诱导不希望的同种异体HLA反应性。在本研究中,我们利用病毒逃避策略来产生表达一组可控内源性肽的APC。由于病毒基因产物的表达阻碍了T细胞对感染细胞的识别,疱疹病毒在初次感染后会终生持续存在。疱疹病毒衍生的蛋白US6、ICP47和UL49.5通过抑制与抗原加工相关的转运体来下调人APC中的内源性抗原呈递。用编码US6、ICP47或UL49.5的逆转录病毒载体转导的EBV转化B细胞系在细胞表面HLA I类表达上表现出稳定下降,并受到mHag特异性CTLs的裂解保护。外源添加mHag肽可完全恢复靶细胞识别。UL49.5显示出最显著的抑制作用,将HLA I类表达和mHag特异性裂解降低高达99%。UL49.5还显著降低了同种异体HLA特异性CTLs介导的同种异体HLA反应性。总之,UL49.5可能是研究和调节内源性抗原呈递的有力新工具。